Aya  Jakobovits net worth and biography

Aya Jakobovits Biography and Net Worth

Director of Adicet Bio
Aya Jakobovits founded Adicet in 2014 and served as its President and CEO until February 2018. She served as a Venture Partner at OrbiMed from 2011-2016. Previously, from 2010-2013, Dr. Jakobovits served as the President and Founding CEO of Kite Pharma, Inc., sold in 2017 to Gilead for $11.9 billion. Before joining Kite Pharma, she served as Executive Vice President, Head of Research and Development at Agensys, Inc., an affiliate of Astellas Pharma Inc. Before Agensys acquisition in 2007 in a deal valued at up to $537 million, Dr. Jakobovits served as Agensys’ Senior Vice President, Technology and Corporate Development and Chief Scientific Officer and led its R&D, clinical and corporate development operations. Prior to Agensys, she served as the Director, Discovery Research and Principal Scientist at Abgenix, Inc., which was spun out of Cell Genesys, Inc. and based on the XenoMouse® technology developed under her leadership. Abgenix was acquired by Amgen Inc. for $2.2 billion.

Dr. Jakobovits received her B.Sc. cum laude from the Hebrew university of Jerusalem, her M.Sc. in Chemistry and Ph.D. in Life Sciences from the Weizmann Institute of Sciences, Israel, and was a postdoctoral fellow at UCSF and Genentech. Dr. Jakobovits is an author of over 50 scientific publications and inventor of over 120 patents.

She is a Director of UCLA Technology Development Corporation and the Alliance for Cancer Gene Therapy.

How old is Aya Jakobovits?

Ms. Jakobovits is currently 69 years old. There are 5 older executives and no younger executives at Adicet Bio. Learn More on Aya Jakobovits' age.

How do I contact Aya Jakobovits?

The corporate mailing address for Ms. Jakobovits and other Adicet Bio executives is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. Adicet Bio can also be reached via phone at (650) 503-9095 and via email at [email protected]. Learn More on Aya Jakobovits' contact information.

Has Aya Jakobovits been buying or selling shares of Adicet Bio?

Aya Jakobovits has not been actively trading shares of Adicet Bio during the past quarter. Most recently, Aya Jakobovits sold 4,000 shares of the business's stock in a transaction on Wednesday, February 16th. The shares were sold at an average price of $14.83, for a transaction totalling $59,320.00. Learn More on Aya Jakobovits' trading history.

Who are Adicet Bio's active insiders?

Adicet Bio's insider roster includes Chen BA (), Jay Elliott (COO), Aya Jakobovits (Director), Chen Schor (CEO), and Andrew Sinclair (Director). Learn More on Adicet Bio's active insiders.

Are insiders buying or selling shares of Adicet Bio?

In the last twelve months, Adicet Bio insiders bought shares 1 times. They purchased a total of 3,125,000 shares worth more than $7,500,000.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 5,900 shares worth more than $8,437.00. The most recent insider tranaction occured on June, 5th when Director Michael Kauffman sold 5,900 shares worth more than $8,437.00. Insiders at Adicet Bio own 19.1% of the company. Learn More about insider trades at Adicet Bio.

Information on this page was last updated on 6/5/2024.

Aya Jakobovits Insider Trading History at Adicet Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2022Sell4,000$14.83$59,320.00View SEC Filing Icon  
2/9/2022Sell8,000$14.03$112,240.00View SEC Filing Icon  
1/5/2022Sell4,000$16.92$67,680.00View SEC Filing Icon  
1/3/2022Sell12,000$18.02$216,240.00View SEC Filing Icon  
6/15/2021Sell3,847$11.16$42,932.52View SEC Filing Icon  
5/20/2021Sell1,792$14.23$25,500.16View SEC Filing Icon  
5/18/2021Sell6,208$14.05$87,222.40View SEC Filing Icon  
5/12/2021Sell10,000$13.23$132,300.00View SEC Filing Icon  
See Full Table

Aya Jakobovits Buying and Selling Activity at Adicet Bio

This chart shows Aya Jakobovits's buying and selling at Adicet Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Adicet Bio Company Overview

Adicet Bio logo
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $0.99
Low: $0.99
High: $0.99

50 Day Range

MA: $1.36
Low: $0.95
High: $1.53

2 Week Range

Now: $0.99
Low: $0.93
High: $3.77

Volume

4,111 shs

Average Volume

1,100,616 shs

Market Capitalization

$81.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81